stemsavelogo

Select Country

877-783-6728 (877-StemSave)

StemSave Blog

MS Stem Cell Treatment Enters Phase II Clinical Trial

Posted by pamela@stemsave.com on Mar 1, 2019 11:01:00 AM

The National Multiple Sclerosis Society is contributing over 1 million dollars to a Phase II clinical trial that utilizes autologous (the patient’s own) mesenchymal stem cells to treat Multiple Sclerosis (MS). Mesenchymal stem cells were selected for this treatment based on their ability to differentiate into neural progenitor cells, which can serve to repair the damaged neurons that result from MS. The cells are recovered from the patient, then expanded and cultured to differentiate into neural cells in clinically significant numbers.

Read More

Topics: MS, clinical trials, multiple sclerosis treatment

MS Phase II Clinical Trial Launched Using Patient Stem Cells

Posted by devin@stemsave.com on Nov 4, 2018 9:44:00 AM

BrainStorm Cell Therapuetics is currently launching a Phase II clinical trial utilizing mesenchymal stem cells (MSCs) that are cultured to develop into neurological components able to treat progressive multiple sclerosis (MS). The proprietary technology called NurOwn uses a patient’s own (autologous) MSCs that are modified outside of the body and returned to repair and support neurons that are attacked in patients with MS. The stem cells are modified to produce growth factors, which support neurons and enhance differentiation and survival of neural cells.

Read More

Topics: multiple sclerosis, MS, autologous stem cells, multiple sclerosis treatment, stem cell treatment

Stem Cells Reverse MS in Breakthrough Clinical Trial

Posted by taylor@stemsave.com on Dec 1, 2017 12:30:00 PM

A team of researchers at the Hadassah Medical Center in Israel has developed a unique method of applying a patient’s own stem cells to restore mobility following progressive multiple sclerosis (MS). MS is an autoimmune disorder in which the body attacks its own neurons and affects millions of people worldwide. Severely progressive MS leads to complete loss of limb function, memory problems, seizures, and even systemic organ failure. This groundbreaking, double-blind, Phase II clinical trial successfully administered autologous (the patient’s own) mesenchymal stem cells, which were cultured and expanded to clinically significant numbers, and then applied directly into the spinal fluid. The treatment simultaneously addressed the two problems of MS - inflammatory immune response and the destruction of the outer coating of neurons that allows for quick signal transduction thereby engendering a significant increase in efficacy.

Read More

Topics: multiple sclerosis, MS, patient's own mesenchymal stem cells, mesenchymal stem cells, autologous stem cells, multiple sclerosis treatment

AAOMS

AAOMS - American Association of Oral and Maxillofacial Surgeons

 

As the industry leader, StemSave is the only stem cell banking service to be designated as an ASI approved program.

    Recent Posts

    Posts by Topic

    see all